Because of limited availability of patient material, we did not study immunity to other known CML antigens such as WT1 or the BCR-ABL fusion region peptides, but we would expect that CTL immunity against these and perhaps other leukemia antigens should be similarly increased. The gene discussed is WT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.